Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Pyridostigmine in Pompe Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between 8 and 60 years of age;~2. Diagnosis of Pompe disease (protein assay, genotyping, and positive clinical signs)~3. No contraindication to pyridostigmine~Exclusion Criteria:~1. Already receive pyridostigmine as part of their normal clinical care at screening~2. Are pregnant - participants will receive a urine pregnancy test at screening~3. Have received acute administration of antibiotic, corticosteroid, or neuromuscular blockade medications within 30 days prior to screening~4. Any other concurrent medical condition which, in the opinion of the study team, would make the subject inappropriate to participate in the assessments

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Acute Dose of Pyridostigmine (Type: EXPERIMENTAL): Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
- Prolonged Use of Pyridostigmine (Type: EXPERIMENTAL): This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).